Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06963710 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
A Phase 2 study of Chronic Hepatitis B Infection, sponsored by Aligos Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06963710: Recruiting Phase 2 study of Chronic Hepatitis B Infection, sponsored by Aligos Therapeutics.
NCT06963710 is a Phase 2 study of Chronic Hepatitis B Infection that is actively recruiting participants, run by Aligos Therapeutics. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06963710, a Phase 2 study of Chronic Hepatitis B Infection, is actively recruiting participants, sponsored by Aligos Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.
Primary Outcome
HBV DNA \<Lower Limit of Quantification \[LLOQ\] (10 IU/mL, target detected or target not detected) at Week 48
Conditions Studied
Interventions
- DRUG ALG-000184
- DRUG TDF
Study Locations (20)
California
- Aligos Investigational Site - Coronado
- Aligos Investigational Site - Garden Grove
- Aligos Investigational Site - Los Angeles
- Aligos Investigational Site - Palo Alto
- Aligos Investigational Site - Pasadena
- Aligos Investigational Site - Rialto
- Aligos Investigational Site - San Francisco
- Aligos Investigational Site - San Jose
Florida
- Aligos Investigational Site - Miami
- Aligos Investigational Site - Miami
Maryland
- Aligos Investigational Site - Baltimore
- Aligos Investigational Site - Chevy Chase
New York
- Aligos Investigational Site - Manhasset
- Aligos Investigational Site - New York
Other
- Aligos Investigational Site - Sliven
- Aligos Investigational Sites - Sofia
Arizona
- Aligos Investigational Site - Chandler
Louisiana
- Aligos Investigational Site - Marrero
Massachusetts
- Aligos Investigational Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
What NCT06963710 shows while recruiting
NCT06963710 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Chronic Hepatitis B Infection appearing as the primary indexed condition, and to 2 interventions - of which ALG-000184 is the first listed.
NCT06963710 names 20 study sites across 9 states, led by California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06963710 about?
NCT06963710 is a clinical study titled "A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)". This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.
What is the current status of trial NCT06963710?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-07-15. Estimated completion is 2028-08.
What conditions does trial NCT06963710 study?
This clinical trial studies the following conditions: Chronic Hepatitis B Infection.
What interventions are being tested in trial NCT06963710?
The interventions under investigation include: ALG-000184 (DRUG), TDF (DRUG).
Who is sponsoring clinical trial NCT06963710?
This trial is sponsored by Aligos Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06963710 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis B Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06963710's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI